NewLimit develops epigenetic reprogramming therapies aimed at treating age-related diseases.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
NewLimit uses AI-driven high-throughput screening to discover epigenetic reprogramming factors that reset cellular age without changing cell type. Has demonstrated successful human cell reprogramming; first drug candidates entering clinical trials next year with $435M funding for multiple shots on goal.